In colorectal cancer, mutations in downstream molecules of EGFR, such as KRAS, NRAS or PI3K, can lead to a loss of response to anti-tumor drugs targeting EGFR and result in a poor prognosis for patients [89,90,91]. Here, EGFR is linked to neoplasm.